10x Genomics, Inc.
NASDAQ:TXGMedical - Healthcare Information Services
+$2.49 today
- Market cap
- $6.93B
- Beta
- 2.11
- P/E (TTM)
- -196.0
- EPS (TTM)
- -$0.18
Volume 2.10M
Average 3.06M
TXG Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
10x Genomics, Inc.NASDAQ: TXG
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow dips below year-ago levels
Q2 FY2026 free cash flow of $15.39M fell 4.6% year over year, behind the +113.5% change in trailing-twelve-month free cash flow. Sequentially, it fell 37.3% from the prior quarter.
Context
- Free cash flow amounted to 20.2% of revenue in FY2025, up 19.3 pp from a year earlier.
- Free cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -4.6% toward the trailing-twelve-month pace of +113.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 130.12M USD
- Year-over-year change
- +2371.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 130.12M | +2371.2% |
| FY2024 | 2024-12-31 | (5.73M) | +91.1% |
| FY2023 | 2023-12-31 | (64.72M) | +60.8% |
| FY2022 | 2022-12-31 | (165.27M) | -34.7% |
| FY2021 | 2021-12-31 | (122.65M) | — |
Free Cash Flow vs competitors
How TXG compares with its peers on the latest reported figures
- TXG's LTM Jun 2026 free cash flow of $121.44M is the 7th largest of the 9 companies compared; the peer median is $400.4M.
- Its year-over-year change of +113.5% is the highest of 9, against a peer median of +6.4%.
- Free cash flow amounts to 19.7% of revenue for TXG, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.27B | +16.5% | +4.1% | 17.2% | |
| LTM Jun 2026 | $939M | -8.9% | +106.3% | 20.9% | |
| LTM Jul 2026 | $559.34M | +11.2% | -5.1% | 19.2% | |
| LTM Jun 2026 | $447.7M | -9.8% | -7.1% | 21.3% | |
| LTM Jun 2026 | $353.1M | +1.6% | +67.1% | 13.6% | |
| LTM Sep 2026 | $308.2M | +37.6% | +6.8% | 25.1% | |
| LTM Jun 2026 | $121.44M | +113.5% | — | 19.7% | |
| LTM Mar 2026 | $94.48M | -23.7% | -3.9% | 109.5% | |
| LTM Sep 2026 | $89.01M | +17.7% | -19.4% | 19.4% | |
| Peer median (excluding TXG) | $400.4M | +6.4% | +0.1% | 20.1% | |
Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.22M) | (166M) | (255.1M) | (182.63M) | (43.54M) |
| Depreciation & Amortization | 28.25M | 33.01M | 43.62M | 43.71M | 43.82M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 95.96M | 136.85M | 166.95M | 140.75M | 109.12M |
| Change in Working Capital | (87.45M) | (39.42M) | 17.34M | 1.25M | 24.94M |
| Accounts Receivables | (34.04M) | (18.95M) | (10.61M) | 26.95M | 6.44M |
| Inventory | (30.13M) | (21.19M) | 7.87M | (9.78M) | 27.95M |
| Accounts Payables | 11.08M | 5.86M | (6.02M) | (3.35M) | (2.13M) |
| Other Working Capital | (34.36M) | (5.14M) | 26.1M | (12.57M) | (7.33M) |
| Other Non-Cash Items | 79K | 1.96M | 11.99M | 3.58M | 1.72M |
| Operating Cash Flow | (21.37M) | (33.61M) | (15.2M) | 6.66M | 136.05M |
| Capital Expenditures | (101.28M) | (131.66M) | (49.52M) | (12.39M) | (5.94M) |
| Acquisitions (Net) | (5.45M) | (4M) | 0 | 0 | (9.27M) |
| Purchases of Investments | 0 | (282.87M) | 0 | (48.88M) | (123.44M) |
| Sales of Investments | 0 | 67.65M | 183.02M | 29.64M | 125.2M |
| Other Investing Activities | 0 | 0 | (923K) | (1M) | 0 |
| Investing Cash Flow | (106.73M) | (350.89M) | 133.49M | (32.63M) | (13.44M) |
| Debt Repayment | (5.03M) | (5.41M) | (5.81M) | 0 | 0 |
| Common Stock Issued | 40.33M | 21.23M | 19.48M | 10.91M | 6.8M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 35.3M | 15.82M | 13.67M | 10.91M | 6.8M |
| Effect of Forex Changes | 234K | (44K) | (33K) | (164K) | 484K |
| Net Change in Cash | (92.57M) | (368.72M) | 131.93M | (15.22M) | 129.9M |
| Free Cash Flow | (122.65M) | (165.27M) | (64.72M) | (5.73M) | 130.12M |
10x Genomics, Inc.
NASDAQ:TXG
Intrinsic Alpha fair value
Locked
Current Price
$57.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.